Overview: Coccidioides Antibody (Cocci Ab) TestIntroduction: The Coccidioides Antibody Test detects antibodies to Coccidioides, indicating valley fever causing fever or lung issues. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected valley fever.
Other Names: Coccidioides Ab Assay, Valley Fever Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Coccidioides antibody testing began in the 1960s with valley fever research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved diagnostic accuracy.
Purpose: Diagnoses valley fever, guides treatment, and monitors antibody levels in patients with fever or lung issues.
Test Parameters: 1. Coccidioides Antibody
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like fever or cough, and list recent travel to endemic areas.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, cough, or travel to endemic areas like the Southwest US. Include current medications, especially antifungals.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antifungal therapy.
Procedural Considerations: Uses an immunoassay to measure Coccidioides antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Recent antifungals may suppress antibody levels. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm valley fever, prompting antifungal therapy. Negative results may require PCR or culture testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation. A pulmonologist referral is advised for lung involvement.
Additional Supporting Tests: Coccidioides PCR, fungal culture, or chest imaging to confirm valley fever or assess lung damage.
Test Limitations: False negatives may occur with early infection. Results require clinical correlation with travel history.
References: IDSA Valley Fever Guidelines, 2023; Clinical Infectious Diseases, Galgiani JN, 2022.
